Evaluation of Malignancy Risk in Scleroderma by Antibody Profile The British Journal of Dermatology

TAKE-HOME MESSAGE

• In this retrospective chart analysis spanning from 2000 to 2017, the authors identified 125 systemic sclerosis patients, including 59 (47.2%) with a cancer diagnosis. Breast (n=15), genitourinary (n=11), and lung (n=10) were the most commonly observed malignancies. The incidence of malignancy was higher in patients with anti-RNAP III antibodies, particularly within 3 years of systemic sclerosis diagnosis.

• This study demonstrated a higher prevalence of malignancy in patients with systemic sclerosis than has been previously reported, which may be related to an older study population, higher incidence of anti-RNAP III, and/or greater disease severity seen in their tertiary care center. Regardless, authors conclude that dermatologists should consider malignancy screening in patients with systemic sclerosis within 3 years of onset.

– Caroline K. Crabtree, MD

Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.